Sai Life Sciences Limited (BOM:544306)
India · Delayed Price · Currency is INR 1,144.20
-16.05 (-1.38%)
At close: Jun 1, 2026
Sai Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 21,925 | 16,946 | 14,652 | 12,171 | 8,696 | |
Revenue Growth (YoY) | 29.38% | 15.66% | 20.38% | 39.97% | 14.44% |
Cost of Revenue | 5,709 | 5,131 | 4,845 | 4,667 | 3,092 |
Gross Profit | 16,216 | 11,814 | 9,807 | 7,505 | 5,603 |
Selling, General & Admin | 6,831 | 5,563 | 5,000 | 4,235 | 3,154 |
Other Operating Expenses | 3,074 | 2,156 | 1,828 | 1,546 | 1,229 |
Operating Expenses | 11,573 | 9,108 | 8,085 | 6,844 | 5,292 |
Operating Income | 4,643 | 2,706 | 1,722 | 660.66 | 311.18 |
Interest Expense | -392.39 | -761.64 | -859.11 | -770.57 | -495.71 |
Interest & Investment Income | - | 175.65 | 135.97 | 106.64 | 70.5 |
Currency Exchange Gain (Loss) | - | 190.76 | 146.26 | 173.02 | 97.84 |
Other Non Operating Income (Expenses) | 491.28 | 1.38 | 8.59 | - | - |
EBT Excluding Unusual Items | 4,742 | 2,312 | 1,154 | 169.75 | -16.19 |
Gain (Loss) on Sale of Assets | - | -18.11 | 0.1 | -5.67 | 113.14 |
Asset Writedown | - | -17.2 | -61.86 | - | - |
Other Unusual Items | -80.01 | - | - | - | - |
Pretax Income | 4,662 | 2,277 | 1,092 | 164.08 | 96.95 |
Income Tax Expense | 1,173 | 575.71 | 264.25 | 64.19 | 34.69 |
Net Income | 3,489 | 1,701 | 828.09 | 99.89 | 62.26 |
Net Income to Common | 3,489 | 1,701 | 828.09 | 99.89 | 62.26 |
Net Income Growth | 105.08% | 105.45% | 729.00% | 60.44% | -89.81% |
Shares Outstanding (Basic) | 210 | 193 | 181 | 181 | 180 |
Shares Outstanding (Diluted) | 212 | 198 | 183 | 182 | 182 |
Shares Change (YoY) | 7.47% | 8.04% | 0.27% | 0.46% | 5.32% |
EPS (Basic) | 16.63 | 8.83 | 4.57 | 0.55 | 0.35 |
EPS (Diluted) | 16.43 | 8.61 | 4.53 | 0.55 | 0.34 |
EPS Growth | 90.83% | 90.07% | 723.64% | 61.77% | -90.41% |
Free Cash Flow | -838.28 | -552.35 | 813.97 | 1,063 | -1,020 |
Free Cash Flow Per Share | -3.95 | -2.79 | 4.45 | 5.83 | -5.62 |
Gross Margin | 73.96% | 69.72% | 66.93% | 61.66% | 64.44% |
Operating Margin | 21.18% | 15.97% | 11.76% | 5.43% | 3.58% |
Profit Margin | 15.91% | 10.04% | 5.65% | 0.82% | 0.72% |
Free Cash Flow Margin | -3.82% | -3.26% | 5.56% | 8.74% | -11.73% |
EBITDA | 6,312 | 3,596 | 2,454 | 1,261 | 916.14 |
EBITDA Margin | 28.79% | 21.22% | 16.75% | 10.36% | 10.54% |
D&A For EBITDA | 1,669 | 889.62 | 731.35 | 600.8 | 604.96 |
EBIT | 4,643 | 2,706 | 1,722 | 660.66 | 311.18 |
EBIT Margin | 21.18% | 15.97% | 11.76% | 5.43% | 3.58% |
Effective Tax Rate | 25.16% | 25.28% | 24.19% | 39.12% | 35.78% |
Revenue as Reported | 22,416 | 17,313 | 14,943 | 12,451 | 8,977 |
Advertising Expenses | - | 50.14 | 30.45 | 11.14 | 51.05 |